NCT04314375: Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis |
|
|
| Recruiting | 4 | 70 | US | Low Dose Budesonide, High Dose Budesonide, Placebo | Bausch Health Americas, Inc. | Ulcerative Colitis | 12/24 | 12/24 | | |
2017-004576-57: Novel budesonide capsules vs. budesonide tablets in patients with ulcerative colitis refractory to standard treatment with mesalazine Neue Budesonid Kapseln vs. Budesonid Tabletten bei Colitis-ulcerosa-Patienten, die gegen die Standardbehandlung mit Mesalazin refraktär sind |
|
|
| Ongoing | 3 | 777 | Europe | Budesonide 9 mg capsules, hard (BUX-PVII prototype), Budesonide 6 mg capsules, hard (BUX-PVII prototype), Prolonged-release capsule, hard, Prolonged-release tablet, CortimentMMX 9 mg | Dr. Falk Pharma GmbH, Dr. Falk Pharma GmbH | Patients with active ulcerative colitis refractory to standard treatment with mesalazine, Patients with ulcerative colitis refractory to standard treatment with mesalazine, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT05341401: Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis |
|
|
| Not yet recruiting | 2/3 | 100 | NA | Budesonide MMX, Prednisolone | Assiut University | Ulcerative Colitis Chronic | 06/23 | 06/24 | | |
NCT05915104: Efficacy and Safety of Budesonide MMX® vs. Budesonide CR for Induction of Remission in Microscopic Colitis |
|
|
| Not yet recruiting | 2 | 80 | NA | Budesonide MMX®, Cortiment®, Budesonide controlled ileal release (CR) capsules, Entocort® | University of Calgary, Ferring Pharmaceuticals | Microscopic Colitis | 09/26 | 12/26 | | |